Latest / Views and News with Clarence Ford / Weight loss drugs like Ozempic, Wegovy and Mounjaro may harm mental health
Transcript
- 0:00Speaker 1: Mkhletse Tosaho, member of the South African Society of Psychiatrists,
- 0:05Speaker 1: a psychiatrist who brings a very compassionate clinical lens to
- 0:09Speaker 1: patient health. So we're going to talk about these GLP-1
- 0:13Speaker 1: receptors and find out if it is all wondrous as
- 0:20Speaker 1: we are hearing the reports that it's just has a wonderful, what?
- 0:26Speaker 1: A wonderful impact on people's expectations. or wonderful outcomes on
- 0:31Speaker 1: their expectations, at least. Welcome to you, Dr. Tosajo. We've
- 0:37Speaker 1: lost Dr. Tosajo, so we're going to be finding Dr.
- 0:42Speaker 1: Tosajo as well. We have maybe, while we can get Dr.
- 0:48Speaker 1: Tosajo on the line, another voice note. Oh, Dr. Tosajo, welcome.
- 0:52Speaker 1: It's great to have you with us.
- 0:53Speaker 2: Hi, yes, thank you for having me.
- 0:57Speaker 1: There you are. So we are seeing a rising use
- 1:02Speaker 1: of prescription drugs for weight loss, and people are really
- 1:07Speaker 1: vouching for the efficacy. I guess it can have a
- 1:12Speaker 1: life-changing effect on people. I know people, there's a semblance
- 1:17Speaker 1: of confidence that returned to them, and that in itself,
- 1:21Speaker 1: I think, is a significant part of the job done,
- 1:23Speaker 1: is it not, Dr. Tosajo?
- 1:27Speaker 2: No, it is. You're correct by saying that. I mean,
- 1:31Speaker 2: the GLP-1 medications are prescribed or indicated for weight loss
- 1:38Speaker 2: in certain individuals. So there are people that should benefit
- 1:44Speaker 2: from it. Like, you know, those are people who are overweight,
- 1:48Speaker 2: people with diabetes, and people who are slightly overweight but
- 1:54Speaker 2: with comorbid conditions that do predispose them to obesity.
- 2:01Speaker 1: But again, I don't think we should assume that rapid
- 2:04Speaker 1: weight loss automatically removes or resolves low self-esteem, does it? 100%.
- 2:12Speaker 2: That's very true. And as I said, so all of
- 2:15Speaker 2: those things are more so medical conditions. I mean, we
- 2:18Speaker 2: do have psychiatric conditions which can lead to people being overweight, depression,
- 2:29Speaker 2: and eating disorders that we do see. But the best
- 2:35Speaker 2: way to treat these would be to address the underlying condition.
- 2:40Speaker 2: And then the weight loss, we usually see it. But
- 2:44Speaker 2: as you said, you know, there is some kind of
- 2:46Speaker 2: benefit to it. But giving just the GLP-1 antagonist or
- 2:54Speaker 2: drugs is not addressing the full issue or the underlying issue.
- 2:59Speaker 1: Okay. Because I know that patients, well, there's a bit
- 3:05Speaker 1: of a disconnect, a mind-body disconnect of sorts. Their physical
- 3:09Speaker 1: appearance changing faster than their self-perception. Are you saying those
- 3:14Speaker 1: are deeper kind of issues? 100%.
- 3:17Speaker 2: 100%. And as you say, so self-esteem and even depressive symptoms,
- 3:25Speaker 2: You might see the weight going off or melting off,
- 3:29Speaker 2: but it doesn't really address the mental struggle that people
- 3:33Speaker 2: go through.
- 3:35Speaker 1: Yeah, so maybe just we're talking about, I think, what
- 3:39Speaker 1: has proven to be a very significant drug. We cannot
- 3:43Speaker 1: necessarily see it in isolation. Is that really the nub
- 3:48Speaker 1: of it all? Pardon? We can't see the drug in
- 3:53Speaker 1: isolation of having an interaction with a professional psychiatrist like yourself.
- 3:59Speaker 1: Is that what you're saying? If you want to maximize
- 4:01Speaker 1: on this efficacy, a psychiatrist or psychologist needs to talk
- 4:05Speaker 1: you through it? Is that the point?
- 4:08Speaker 2: That is the point, exactly. So we would rather have
- 4:15Speaker 2: the doctors that are seeing these patients to at least
- 4:18Speaker 2: refer them to their psychologist and or the psychiatrist to assist,
- 4:24Speaker 2: to at least assess the patient's mental health during the process,
- 4:31Speaker 2: this process of hoi ku.
- 4:33Speaker 1: So there's a mental alignment with physically taking the drug,
- 4:38Speaker 1: of course. So let's get a sense of the issues
- 4:41Speaker 1: here because we've got these GLP-1 drugs. We know that
- 4:45Speaker 1: they work on the brain's reward centers to suppress appetite.
- 4:50Speaker 1: So from a psychiatric perspective, how does altering, I guess
- 4:54Speaker 1: it does alter those pathways, how does it affect mood, motivation,
- 4:59Speaker 1: maybe overall emotional regulation?
- 5:04Speaker 2: So right now, the GLP-1 drugs have not been used
- 5:12Speaker 2: well-researched in terms of the long-term effects that they do
- 5:16Speaker 2: have on someone's mental health. But we have seen that
- 5:21Speaker 2: some people are starting to come up with some kind
- 5:27Speaker 2: of mood changes and mood behaviors, people who are on
- 5:30Speaker 2: these GLP drugs. Not to say that is the cause,
- 5:34Speaker 2: but there have been some reports there. So we're paying
- 5:38Speaker 2: close attention to it. But as we said, before someone...
- 5:42Speaker 2: does go on this GLP-1, we have to investigate why
- 5:46Speaker 2: the person is obese, first of all, and then if
- 5:49Speaker 2: there are any underlying mental issues that the person is
- 5:53Speaker 2: going through. So as much as, yes, the GLP-1 does
- 5:57Speaker 2: affect some neuroreceptors in the brain, we haven't really seen
- 6:03Speaker 2: the link between those receptors and the ones that are
- 6:07Speaker 2: linked to mental illness. But what I can say, there
- 6:11Speaker 2: is definitely a bidirectional relationship between weight and mental health,
- 6:21Speaker 2: particularly weight gain.
- 6:24Speaker 1: And I think you've referred to underlying psychiatric conditions. Give
- 6:29Speaker 1: us typical examples of such conditions.
- 6:34Speaker 2: So the main one, which is the one we see commonly,
- 6:37Speaker 2: is depression. depression or major depressive disorder where when someone
- 6:42Speaker 2: is depressed, just the fact that they are depressed, it's
- 6:46Speaker 2: linked to significant weight gain. As you know, with depression,
- 6:50Speaker 2: that is the lack of serotonin or reduction of serotonin neurotransmitters.
- 6:58Speaker 2: But at the same time, even when you are depressed,
- 7:02Speaker 2: being on an antidepressant can also lead to weight gain
- 7:07Speaker 2: and stuff like that. Then we also have anxiety, which again,
- 7:11Speaker 2: more or less the same in terms of the management.
- 7:15Speaker 2: Some antidepressants can cause weight gain. The other one is
- 7:21Speaker 2: binge eating disorder, which is a mental illness, part of
- 7:26Speaker 2: the eating disorders cluster where someone eats excessively. I mean,
- 7:32Speaker 2: that can lead to obesity. But then we have like um,
- 7:37Speaker 2: other serious mental illnesses, bipolar, schizophrenia, um, the medication that
- 7:44Speaker 2: we give also can lead to obesity.
- 7:48Speaker 1: My guest is Dr. Makhalatse Dosako, a member of the
- 7:51Speaker 1: South African Society of Psychiatrists. Uh, if you wish to
- 7:55Speaker 1: be anonymous, maybe you want to text, uh, your question.
- 7:58Speaker 1: Maybe you have flagged such issues that have accompanied this
- 8:03Speaker 1: journey with, um, with the drugs, maybe Ozempic, Wegovi, Monjaro.
- 8:11Speaker 1: It appears as if it could possibly impact your mental health.
- 8:17Speaker 1: And that is why we're having this conversation. And you,
- 8:19Speaker 1: of course, can ask your question or make your statements
- 8:21Speaker 1: via WhatsApp at 0725671567. You can call anytime on 021-446-0567.
- 8:23Speaker 1: And we'll prioritize your call on that number. I see
- 8:34Speaker 1: regulatory bodies like the FDA, they've noted, quote unquote, that
- 8:40Speaker 1: clinical trials don't show a direct causal link to severe depression.
- 8:48Speaker 1: But thousands of patients report feeling emotionally flat or anxious.
- 8:52Speaker 1: So it does appear as if there's a bit of
- 8:55Speaker 1: a gap between clinical trial data and what real world
- 8:59Speaker 1: patient reports, the people that you are seeing in your practice, doctor? Yes.
- 9:05Speaker 2: For me, honestly, I suspect that we need to screen
- 9:10Speaker 2: people more. As I said, my main message here is
- 9:14Speaker 2: that we need to know what is the cause of
- 9:17Speaker 2: this obesity. Screen for mental illnesses or other psychiatric conditions
- 9:23Speaker 2: while prescribing these GLP-1 drugs, as they have shown recently.
- 9:30Speaker 2: good results and a lot of people hence those research
- 9:36Speaker 2: results but I think as you had rightly said we
- 9:42Speaker 2: still see people even when the weight is off the
- 9:46Speaker 2: self-esteem is still low the mood is still.
- 9:48Speaker 1: Low and you'd expect the opposite.
- 9:51Speaker 2: To happen actually exactly exactly Well.
- 9:54Speaker 1: I know it's working for some people. There's a there's
- 9:58Speaker 1: a great kind of confidence that has returned and I
- 10:00Speaker 1: guess for others it isn't quite working on the same
- 10:03Speaker 1: basis a message in from anonymous my daughter is on
- 10:07Speaker 1: the retro ride peptide if someone is taking medication my
- 10:13Speaker 1: daughter was hearing voices should she be taking this.
- 10:20Speaker 2: So if her daughter is taking medication for those voices,
- 10:25Speaker 2: as we said, we haven't seen any link between or
- 10:29Speaker 2: contraindications in terms of the GLP drugs as opposed to
- 10:36Speaker 2: our medication in psychiatry. So if her daughter is taking
- 10:41Speaker 2: medication that is managing those voices, I don't see any
- 10:45Speaker 2: problems here.
- 10:47Speaker 1: Okay, so the GPs essentially are writing the scripts. It's
- 10:51Speaker 1: being described rapidly, and sometimes it's sourced even by bypassing
- 10:58Speaker 1: a GP. And you're saying, please include an interaction or
- 11:04Speaker 1: interactions with a specialist like yourself together with that prescription. Exactly.
- 11:10Speaker 2: That's exactly what I'm saying. I mean, we know that
- 11:14Speaker 2: the instrument GLP-1 drugs work very well for obesity, you know,
- 11:20Speaker 2: and they do improve self-esteem in other people. But as
- 11:25Speaker 2: you said, you know, we have seen people who are
- 11:28Speaker 2: still having these low moods, these ongoing low self-esteem despite
- 11:34Speaker 2: the weight loss.
- 11:37Speaker 1: Okay, another comment, Anne, on the topic of From what
- 11:41Speaker 1: I hear, the GLP-1 drugs are improving mental health. Existing
- 11:46Speaker 1: mental health issues may not change, but the GLP-1 aren't
- 11:49Speaker 1: creating these issues. So what's the problem then? Yes.
- 11:54Speaker 2: So what we are seeing is right now we haven't
- 11:58Speaker 2: seen the long-term brain function or effects of these GLP-1s
- 12:05Speaker 2: on the brain functioning for now. So as the commenter
- 12:09Speaker 2: rightfully said, you know, we're not, A lot of people
- 12:13Speaker 2: have said that they feel much better with the weight loss.
- 12:17Speaker 2: But what we are saying is, remember, obesity has other causes.
- 12:23Speaker 2: It doesn't have to just be eating. So we are saying,
- 12:28Speaker 2: please consult a mental health professional while you're taking these
- 12:33Speaker 2: medications as well.
- 12:34Speaker 1: Okay, so let's go there. Let's understand that. You say...
- 12:37Speaker 1: essentially that for many people living with obesity, food obviously
- 12:42Speaker 1: acting as maybe a comfort or a coping mechanism for stress.
- 12:47Speaker 1: Help us to understand what happens to that person's mental
- 12:50Speaker 1: well-being when that coping mechanism, and we're talking about eating,
- 12:54Speaker 1: is stripped away overnight by an injection. What happens?
- 12:58Speaker 2: Exactly. So those coping mechanisms, as we said, And, you know,
- 13:03Speaker 2: the impact of weight loss can also impact on the
- 13:07Speaker 2: individual's relationship with others at work or home. And especially
- 13:11Speaker 2: with the rapid weight loss, they can then start being
- 13:14Speaker 2: seen as different or people would start responding to them differently.
- 13:19Speaker 2: And then now as they engage in new activities that
- 13:22Speaker 2: they weren't previously able to. So the job you want
- 13:26Speaker 2: itself for weight loss is not necessarily a harmful strategy
- 13:30Speaker 2: because but the mind and body are intimately connected and
- 13:35Speaker 2: the complex emotional layers attached to weight and weight loss
- 13:38Speaker 2: and the changing emotional relationship with food. So what we're
- 13:43Speaker 2: saying is, you know, and then as we say, the
- 13:46Speaker 2: physical changes of weight loss can result in a sense
- 13:48Speaker 2: of emotional disconnect. So how this person feels about their
- 13:52Speaker 2: body against what they see in the mirror and in
- 13:56Speaker 2: So there are also risks of increased stress and anxiety
- 14:00Speaker 2: due to internal or external pressure to maintain these results.
- 14:06Speaker 2: And in everything, they now add up to changes in
- 14:09Speaker 2: thoughts about oneself and others, their relationships, their moods, their behaviors,
- 14:14Speaker 2: and even social interactions, which can all benefit from the
- 14:18Speaker 2: support of a mental health professional as you can navigate
- 14:22Speaker 2: these changes.
- 14:24Speaker 1: In my conversations with many people within my universe who
- 14:29Speaker 1: have gone to GLP-1s and they're raving about that particular decision,
- 14:34Speaker 1: we talk about, I think, let's call it physical transformation.
- 14:40Speaker 1: But is it really a physical transformation or is it
- 14:42Speaker 1: an identity shift that is being sought?
- 14:46Speaker 2: Exactly.
- 14:48Speaker 1: It's a question. It's a question.
- 14:49Speaker 2: Yeah. That is a good question.
- 14:52Speaker 1: Okay. Yeah.
- 14:54Speaker 2: It's both, basically. You know, there's that physical change. As
- 14:57Speaker 2: I have said, you know, you start navigating through this
- 15:01Speaker 2: new person that you're seeing in the mirror. And in that,
- 15:03Speaker 2: then you see this identity change. And because it happens
- 15:07Speaker 2: so rapidly, it can affect a person's mood, you know,
- 15:13Speaker 2: a person's relationship, how they navigate through life with this
- 15:17Speaker 2: new sense of self.
- 15:18Speaker 1: Hmm. Okay, so that is the question then. Why does
- 15:22Speaker 1: rapid weight loss sometimes then exacerbate anxiety rather than curing it?
- 15:33Speaker 1: It's also a question. Okay, but you're saying those are
- 15:36Speaker 1: the underlying maybe mental conditions that need to be dealt
- 15:39Speaker 1: with as well.
- 15:41Speaker 2: Exactly.
- 15:43Speaker 1: Sorry, I'm learning on the trot here. I'm learning on
- 15:46Speaker 1: the trot. I want to take people with me. Okay,
- 15:50Speaker 1: just why is it so easy maybe to source GLP-1s
- 15:53Speaker 1: off-label or online these days as well? That's not legal,
- 15:57Speaker 1: is it?
- 15:59Speaker 2: It is illegal, yes. So it's not legal because it
- 16:03Speaker 2: is a prescription medication. And we also don't know what
- 16:11Speaker 2: these online GLPs are mixed with. So it's really important
- 16:17Speaker 2: that people get these medications through a licensed practitioner.
- 16:23Speaker 1: Yeah, you can't vouch for the integrity of the product
- 16:25Speaker 1: you're saying. And I think that's very important. Are there
- 16:30Speaker 1: maybe specific patient profiles who should be heeding this concern
- 16:35Speaker 1: that you're expressing? Yes.
- 16:39Speaker 2: So.
- 16:42Speaker 2: People who cannot be on GLP-1s, especially in my field,
- 16:47Speaker 2: you know, in the psychiatric field, are people who have
- 16:50Speaker 2: anorexia and bulimia.
- 16:52Speaker 1: Okay.
- 16:53Speaker 2: But the problem is when, you know, this GLP-1 is
- 16:57Speaker 2: prescribed by someone who's not a mental health provider and
- 17:01Speaker 2: doesn't know that the person has an eating disorder or
- 17:05Speaker 2: that they can obtain it illicitly. So that's the issue.
- 17:09Speaker 2: So the people that should be on GLP-1 or that
- 17:13Speaker 2: can be on GLP-1, as I had mentioned in my introduction,
- 17:16Speaker 2: is that people with increased body mass index of more
- 17:20Speaker 2: than 30 and people with BMIs of more than 27
- 17:25Speaker 2: but with a weight-related comorbidity like diabetes or cholesterol. And then,
- 17:32Speaker 2: of course, people who have diabetes, type 2 diabetes and obesity.
- 17:38Speaker 1: Okay, so I guess we should be asking for those
- 17:41Speaker 1: red flag, maybe mental health systems that maybe somebody or
- 17:46Speaker 1: their loved one should look out for after starting Ozempic
- 17:51Speaker 1: or similar medications. What should we be watching out for?
- 17:56Speaker 2: So, you mean after starting.
- 17:58Speaker 1: Or just before starting? After starting, red flag mental health symptoms.
- 18:02Speaker 1: Is this something that you should watch out for?
- 18:05Speaker 2: Yes, so... If the person starts experiencing numbing of emotions,
- 18:14Speaker 2: lowered mood, and less interest in other usually pleasurable activities,
- 18:19Speaker 2: that should be a call for concern because these are
- 18:23Speaker 2: like classic symptoms of, you know, depression that we note.
- 18:29Speaker 2: So once you start experiencing those, then please seek assistance.
- 18:33Speaker 2: Not to say that you have a major depressive disorder.
- 18:36Speaker 2: but it does mean that you can be at risk
- 18:39Speaker 2: of developing.
- 18:40Speaker 1: Anonymous writes, my husband is on Ozempic for type 2 diabetes.
- 18:45Speaker 1: It is incredibly effective and weight loss has been slow,
- 18:47Speaker 1: but general health improvements have been fantastic. Okay, it's a statement.
- 18:55Speaker 1: You don't need to comment on the statement.
- 18:57Speaker 2: We're happy for the husband.
- 18:59Speaker 1: Yeah, no, for sure. When it's working, that's good news.
- 19:02Speaker 1: So listen, if I'm on Ozempic and my mood is dipping,
- 19:07Speaker 1: what's the protocol? Do I stop the drug immediately or
- 19:10Speaker 1: do I work through it with a multidisciplinary team? What's
- 19:14Speaker 1: your advice?
- 19:15Speaker 2: Yes, so I would definitely advise that you seek help.
- 19:21Speaker 2: whether it's with like your GP some GPs have a
- 19:25Speaker 2: very good interest in mental health issues and then you
- 19:29Speaker 2: can also go to a psychologist but ideally psychiatrists especially
- 19:35Speaker 2: with an eating disorders interest are the ones that you
- 19:39Speaker 2: can go to because they're very much specialized in this
- 19:43Speaker 2: so whenever you feel like your mood is dipping despite
- 19:48Speaker 2: you having lost the weight feeling more, I guess, lighter,
- 19:52Speaker 2: but you're starting to experience these other symptoms, please, please
- 19:57Speaker 2: seek help immediately.
- 20:00Speaker 1: And just maybe from your vantage point, what percentage of
- 20:06Speaker 1: people that have embraced these GLP-1 drugs are suffering as
- 20:11Speaker 1: a consequence of taking it.
- 20:14Speaker 2: So I feel like that would be like a skewed
- 20:16Speaker 2: view because I do see that it wouldn't be a
- 20:20Speaker 2: representation of the whole population of people in GLP-1. But
- 20:24Speaker 2: we do see people who do come in talking about
- 20:29Speaker 2: how their mood is still low. I think, as we said,
- 20:33Speaker 2: there's a lot of people who are going through things
- 20:36Speaker 2: And then they think that, you know, that maybe the
- 20:38Speaker 2: weight is the reason for this. I mean, even with
- 20:41Speaker 2: the weight loss, they see that, no, actually, there's more
- 20:45Speaker 2: things that they are going through. So the expectation that, okay,
- 20:48Speaker 2: once I lose the weight, then I should be fine.
- 20:52Speaker 2: And then if that doesn't happen, I mean, they continue
- 20:54Speaker 2: being anxious or depressed. And then that's when they do
- 20:58Speaker 2: come to us. So they even tell us, you know, doc,
- 21:00Speaker 2: I lost so much weight, but, you know, I'm still
- 21:03Speaker 2: feeling this way. So I wouldn't be to say like, okay,
- 21:07Speaker 2: this is a percentage of people, but we are seeing
- 21:10Speaker 2: a trend, I guess, if I could put it that way.
- 21:14Speaker 2: I don't know if you know, like before the GOP ones,
- 21:16Speaker 2: you know, people used to go for bypass. And even then,
- 21:20Speaker 2: you know, after the bypass, the weight loss is off.
- 21:23Speaker 2: I mean, the weight is off. It would still present with,
- 21:27Speaker 2: you know, these mood changes.
- 21:30Speaker 1: Yeah. I think this has been such an important heads-up, Dr.
- 21:35Speaker 1: Mahlati Tosaka. We can't thank you enough. A member of
- 21:39Speaker 1: the South African Society of Psychiatrists, a relatively new drug.
- 21:43Speaker 1: Hopefully not too much remains to be discovered, as a contraindication,
- 21:50Speaker 1: at least. But I know that it's brought some confidence
- 21:55Speaker 1: to people, and that is a big portion of the
- 21:58Speaker 1: job done, is it not?